Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Food Safety Clear all
Completed Phase 1 Interventional

Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients

NCT02960074
View directory record Official record
Conditions
Peanut Allergy
Interventions
Fecal Microbiota Capsule
Biological
Lead sponsor
Rima Rachid
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

NCT06144697
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986465, Placebo, Pegasys, Famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910
View directory record Official record
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

NCT03852446
View directory record Official record
Conditions
Healthy
Interventions
Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 21, 2026, 3:56 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

NCT05476497
View directory record Official record
Conditions
Peanut Allergy
Interventions
VLP Peanut, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

NCT03199339
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBA-7371, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple-Dose Study of SB1578

NCT01235871
View directory record Official record
Conditions
Healthy Volunteer
Interventions
SB1578, Placebo
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of E2086 in Healthy Adult Participants

NCT06481488
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children

NCT04492683
View directory record Official record
Conditions
Cow's Milk Allergy
Interventions
DBV1605
Combination Product
Lead sponsor
DBV Technologies
Industry
Eligibility
29 Days to 24 Months
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

NCT01445795
View directory record Official record
Conditions
Hepatitis C
Interventions
200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study and Food Effect Study for AG181

NCT06286033
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-181, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BLU-808 in Healthy Adult Participants

NCT06948032
View directory record Official record
Conditions
Healthy Participants
Interventions
BLU-808, Placebo, Midazolam
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
19 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

NCT01297582
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
ONO-6950
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

NCT00726427
View directory record Official record
Conditions
Healthy
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects of Single Oral Dose of 600mg TR-701

NCT00671359
View directory record Official record
Conditions
Healthy
Interventions
TR-701 600mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460
View directory record Official record
Conditions
Dyslipidemia, Healthy Volunteers
Interventions
TAP311
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

NCT04882150
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986196, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers

NCT00449774
View directory record Official record
Conditions
Mental Disorders
Interventions
Lamotrigine IR tablets, Lamotrigine ODT tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety

NCT05684640
View directory record Official record
Conditions
Healthy
Interventions
Rodatristat Ethyl, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of AG-221 in Healthy Male Subjects

NCT02218346
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG221
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

NCT01475981
View directory record Official record
Conditions
Healthy
Interventions
JTK-853 or Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1Phase 2 Interventional

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

NCT05440643
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
4 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

NCT01955109
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
7 Years to 56 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 21, 2026, 3:56 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Calcium-Rich Food Versus Calcium Carbonate for Bone Health

NCT07763509
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Bone Health in Perimenopausal Women, Menopause Related Conditions, Fracture Healing
Interventions
500 mg calcium from milk-derived minerals, Calcium Carbonate 500 MG
Other · Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 21, 2026, 3:56 PM EDT